The_DT International_NP Sepsis_NP Forum_NP 's_POS controversies_NNS in_IN sepsis_NN :_: corticosteroids_NNS should_MD be_VB used_VBN to_TO treat_VB septic_JJ shock_NN Abstract_NP |_SYM The_DT use_NN of_IN corticosteroids_NNS in_IN septic_JJ shock_NN remains_VBZ controversial_JJ ._SENT It_PP has_VBZ been_VBN demonstrated_VBN that_IN high_JJ doses_NNS of_IN steroids_NNS (_( 30_CD mg/kg_NN methylprednisolone_NN )_) for_IN short_JJ periods_NNS of_IN time_NN are_VBP not_RB beneficial_JJ ._SENT More_RBR recent_JJ studies_NNS using_VBG smaller_JJR doses_NNS (_( 200_CD --_: 300_CD mg/day_NN hydrocortisone_NN )_) for_IN longer_JJR periods_NNS of_IN time_NN have_VBP shown_VBN beneficial_JJ effects_NNS ._SENT These_DT positive_JJ effects_NNS have_VBP included_VBN reversal_NN of_IN shock_NN ,_, trends_NNS toward_IN decreased_VBN organ_NN system_NN dysfunction_NN and_CC decreased_VBD mortality_NN ._SENT Based_VBN on_IN the_DT high_JJ proportion_NN of_IN patients_NNS who_WP have_VBP relative_JJ adrenal_JJ insufficiency_NN ,_, the_DT benefits_NNS of_IN low_JJ doses_NNS of_IN steroids_NNS and_CC the_DT minimal_JJ risks_NNS ,_, steroids_NNS should_MD be_VB used_VBN to_TO treat_VB septic_JJ shock_NN ._SENT corticosteroids_NNS ,_, relative_JJ adrenal_JJ insufficiency_NN ,_, septic_JJ shock_NN ,_, survival_NN ,_, In_IN the_DT early_JJ 1980s_NNS we_PP were_VBD big_JJ proponents_NNS of_IN using_VBG corticosteroids_NNS in_IN septic_JJ shock_NN ,_, whereas_IN in_IN the_DT late_JJ 1980s_NNS ,_, following_VBG publication_NN of_IN the_DT findings_NNS of_IN the_DT Veterans_NPS Administration_NP Systemic_NP Sepsis_NP Cooperative_NP Study_NP Group_NP on_IN corticosteroids_NNS in_IN sepsis_NN and_CC those_DT of_IN the_DT study_NN of_IN steroids_NNS in_IN sepsis_NN conducted_VBN by_IN Bone_NP and_CC colleagues_NNS ,_, we_PP thought_VBD corticosteroids_NNS were_VBD a_DT bad_JJ idea_NN ._SENT In_IN fact_NN ,_, subsequently_RB ,_, two_CD meta-analyses_NNS concluded_VBD that_IN steroids_NNS were_VBD not_RB beneficial_JJ in_IN sepsis_NN and_CC septic_JJ shock_NN ._SENT Based_VBN on_IN recent_JJ data_NNS ,_, there_EX is_VBZ enough_RB evidence_NN to_TO suggest_VB that_IN we_PP probably_RB should_MD be_VB using_VBG corticosteroids_NNS in_IN our_PP$ septic_JJ shock_NN patients_NNS ._SENT Although_IN we_PP support_VBP the_DT use_NN of_IN steroids_NNS for_IN treating_VBG septic_JJ shock_NN ,_, we_PP clearly_RB need_VBP a_DT large_JJ trial_NN in_IN this_DT area_NN ._SENT In_IN fact_NN ,_, we_PP are_VBP starting_VBG a_DT prospective_JJ ,_, randomized_VBD ,_, double-blind_JJ trial_NN in_IN Europe_NP that_WDT will_MD enroll_VB large_JJ numbers_NNS of_IN patients_NNS with_IN septic_JJ shock_NN (_( the_DT CORTICUS_NP study_NN )_) ._SENT In_IN 1984_CD ,_, our_PP$ group_NN showed_VBD that_IN there_EX was_VBD a_DT short_JJ period_NN of_IN time_NN with_IN a_DT difference_NN in_IN mortality_NN between_IN a_DT steroid-treated_JJ group_NN and_CC a_DT control_NN group_NN ,_, and_CC that_IN there_EX was_VBD a_DT significant_JJ reversal_NN in_IN shock_NN between_IN the_DT groups_NNS at_IN 24_CD hours_NNS ._SENT We_PP stated_VBD at_IN that_DT time_NN that_IN perhaps_RB we_PP should_MD be_VB giving_VBG steroids_NNS for_IN a_DT longer_JJR period_NN of_IN time_NN rather_RB than_IN just_RB two_CD doses_NNS ._SENT This_DT approach_NN was_VBD likely_JJ to_TO reverse_VB shock_NN in_IN more_JJR patients_NNS and_CC perhaps_RB improve_VB survival_NN ._SENT There_EX has_VBZ clearly_RB been_VBN a_DT change_NN in_IN thinking_VBG of_IN how_WRB steroids_NNS should_MD be_VB used_VBN ,_, in_IN treating_VBG both_DT septic_JJ shock_NN and_CC the_DT acute_JJ respiratory_JJ distress_NN syndrome_NN ._SENT Older_JJR studies_NNS used_VBN large_JJ doses_NNS for_IN short_JJ periods_NNS of_IN time_NN ,_, and_CC were_VBD given_VBN early_RB in_IN the_DT treatment_NN --_: typically_RB one_CD or_CC two_CD doses_NNS of_IN methylprednisolone_NN (_( 30_CD mg/kg_NN )_) ._SENT This_DT was_VBD often_RB done_VBN before_IN any_DT organisms_NNS were_VBD identified_VBN ,_, and_CC hence_RB using_VBG corticosteroids_NNS might_MD be_VB associated_VBN with_IN an_DT increased_VBN incidence_NN of_IN complications_NNS related_VBN to_TO superinfections_NNS ._SENT However_RB ,_, more_JJR recent_JJ studies_NNS recommend_VBP smaller_JJR doses_NNS of_IN steroids_NNS ,_, used_VBN for_IN longer_JJR periods_NNS and_CC given_VBN even_RB later_RBR in_IN the_DT course_NN of_IN the_DT disease_NN ._SENT During_IN septic_JJ shock_NN there_EX is_VBZ an_DT important_JJ problem_NN of_IN relative_JJ adrenal_JJ insufficiency_NN ._SENT This_DT causes_VBZ adrenergic_JJ receptor_NN desensitization_NN --_: a_DT decreased_VBN number_NN of_IN both_DT alpha-_NN and_CC beta-adrenergic_JJ receptors_NNS ._SENT This_DT is_VBZ either_RB related_VBN to_TO sepsis_NN itself_PP or_CC to_TO the_DT use_NN of_IN vasopressors_NNS for_IN long_JJ periods_NNS of_IN time_NN ._SENT Corticosteroids_NNS may_MD help_VB with_IN the_DT resensitization_NN of_IN these_DT receptors_NNS ,_, leading_VBG to_TO haemodynamic_JJ improvement-decreasing_VBG catecholamine_NN requirements_NNS ,_, reversal_NN of_IN shock_NN and_CC perhaps_RB even_RB reversal_NN of_IN organ_NN system_NN failure_NN ._SENT All_DT of_IN these_DT effects_NNS may_MD decrease_VB mortality_NN ._SENT Annane_NP and_CC colleagues_NNS found_VBD the_DT highest_JJS 28-day_JJ mortality_NN (_( 82_CD %_NN )_) in_IN patients_NNS who_WP had_VBD high_JJ baseline_JJ cortisol_NN levels_NNS and_CC who_WP did_VBD not_RB respond_VB to_TO adrenocorticotrophic_JJ hormone_NN (_( ACTH_NP )_) by_IN increasing_VBG cortisol_NN levels_NNS by_IN greater_JJR than_IN 9_CD mug/dl_NN ._SENT If_IN one_CD looks_NNS at_IN relative_JJ adrenal_JJ insufficiency_NN in_IN terms_NNS of_IN nonresponders_NNS to_TO ACTH_NP (_( <=_NN 9_CD g/dl_NN )_) ,_, then_RB the_DT mortality_NN in_IN that_DT group_NN was_VBD 72_CD %_NN ,_, whereas_IN in_IN those_DT who_WP did_VBD respond_VB to_TO ACTH_NP the_DT mortality_NN was_VBD 32_CD %_NN --_: more_JJR than_IN double_RB ._SENT How_WRB common_NN is_VBZ relative_JJ adrenal_JJ insufficiency_NN ?_SENT In_IN the_DT study_NN conducted_VBN by_IN Annane_NP and_CC colleagues_NNS it_PP was_VBD 54_CD %_NN ,_, but_CC in_IN some_DT recent_JJ data_NN there_EX are_VBP suggestions_NNS that_IN between_IN two-thirds_NNS and_CC three-quarters_NNS of_IN patients_NNS with_IN septic_JJ shock_NN may_MD have_VB relative_JJ adrenal_JJ insufficiency_NN ._SENT Therefore_RB corticosteroids_NNS would_MD be_VB helpful_JJ in_IN many_JJ patients_NNS ._SENT Clinical_JJ data_NNS looking_VBG at_IN the_DT increase_NN in_IN mean_JJ arterial_JJ pressure_NN after_IN noradrenaline_NN (_( norepinephrine_NN )_) administration_NN show_VBP that_IN there_EX is_VBZ a_DT greater_JJR response_NN to_TO noradrenaline_NN in_IN patients_NNS with_IN normal_JJ adrenal_JJ function_NN than_IN in_IN those_DT with_IN impaired_JJ adrenal_JJ function_NN ._SENT However_RB ,_, when_WRB one_PP gives_VBZ low_JJ doses_NNS of_IN corticosteroids_NNS to_TO patients_NNS with_IN impaired_JJ adrenal_JJ function_NN the_DT responses_NNS to_TO noradrenaline_NN move_NN closer_RBR together_RB ,_, so_IN that_WDT there_EX are_VBP no_RB longer_RBR statistical_JJ differences_NNS in_IN the_DT noradrenaline_NN effects_NNS of_IN increasing_VBG blood_NN pressure_NN ._SENT The_DT prospective_JJ ,_, randomized_VBD ,_, double_JJ blind_JJ study_NN conducted_VBN by_IN Bollaert_NP and_CC colleagues_NNS looked_VBD at_IN 41_CD patients_NNS who_WP required_VBD catecholamines_NNS for_IN more_JJR than_IN 48_CD hours_NNS and_CC had_VBD been_VBN in_IN shock_NN for_IN 5_CD --_: 6_CD days_NNS ._SENT By_IN that_DT time_NN the_DT patient_NN 's_POS infectious_JJ organisms_NNS had_VBD most_RBS likely_RB been_VBN identified_VBN and_CC they_PP were_VBD probably_RB on_IN appropriate_JJ antibiotics_NNS ,_, so_IN there_EX were_VBD few_JJ problems_NNS in_IN terms_NNS of_IN complications_NNS of_IN corticosteroids_NNS ._SENT Patients_NNS were_VBD given_VBN 100_CD mg_NN hydrocortisone_NN intravenously_RB three_CD times_NNS a_DT day_NN for_IN 5_CD days_NNS ._SENT Treatment_NN was_VBD discontinued_VBN if_IN shock_NN did_VBD not_RB reverse_VB ._SENT If_IN shock_NN reversed_VBD ,_, then_RB treatment_NN was_VBD continued_VBN with_IN half_DT doses_NNS for_IN 3_CD days_NNS and_CC quarter_NN doses_NNS for_IN another_DT 3_CD days_NNS and_CC stopped_VBN ._SENT There_EX was_VBD significant_JJ shock_NN reversal_NN at_IN 7_CD days_NNS ,_, and_CC 28-day_JJ mortality_NN showed_VBD a_DT trend_NN toward_IN significance_NN (_( 63_CD %_NN versus_IN 32_CD %_NN )_) ._SENT Briegel_NP and_CC colleagues_NNS performed_VBD a_DT prospective_JJ ,_, randomized_VBD ,_, double-blind_JJ ,_, single-centre_NN study_NN in_IN hyperdynamic_JJ septic_JJ shock_NN patients_NNS ._SENT They_PP enrolled_VBD septic_JJ patients_NNS who_WP were_VBD on_IN vasopressors_NNS and_CC had_VBD been_VBN in_IN shock_NN for_IN at_IN least_JJS 3_CD days_NNS ._SENT While_IN on_IN vasopressors_NNS ,_, patients_NNS were_VBD given_VBN a_DT bolus_NN of_IN 100_CD mg_NN hydrocortisone_NN or_CC placebo_NN ,_, followed_VBN by_IN a_DT continuous_JJ infusion_NN of_IN 0.18_CD mg/kg_NN per_IN hour_NN of_IN hydrocortisone_NN or_CC placebo_NN ._SENT In_IN addition_NN to_TO a_DT decreased_VBN mean_JJ time_NN for_IN shock_NN reversal_NN ,_, there_RB also_RB seemed_VBD to_TO be_VB a_DT trend_NN toward_IN decreased_VBN organ_NN system_NN dysfunction_NN in_IN the_DT steroid-treated_JJ group_NN as_IN compared_VBN with_IN the_DT control_NN group_NN ._SENT A_DT multicentre_NN ,_, prospective_JJ ,_, randomized_VBD ,_, double-blind_JJ French_JJ study_NN involved_VBD 300_CD patients_NNS enrolled_VBN early_RB after_IN the_DT onset_NN of_IN shock_NN ._SENT Among_IN nonresponders_NNS (_( <=_NN 9_CD g/dl_NN increase_NN in_IN baseline_JJ cortisol_NN after_IN ACTH_NP )_) ,_, there_EX was_VBD greater_JJR survival_NN in_IN the_DT steroid-treated_JJ group_NN as_IN compared_VBN with_IN the_DT placebo_NN group_NN ._SENT Interestingly_RB ,_, there_EX was_VBD a_DT trend_NN toward_IN a_DT higher_JJR mortality_NN in_IN those_DT patients_NNS who_WP were_VBD responders_NNS and_CC treated_VBN with_IN steroids_NNS ._SENT Therefore_RB ,_, it_PP is_VBZ important_JJ to_TO evaluate_VB corticosteroids_NNS in_IN a_DT larger_JJR group_NN of_IN patients_NNS ,_, evaluating_VBG both_DT responders_NNS and_CC nonresponders_NNS ._SENT In_IN addition_NN to_TO efficacy_NN ,_, which_WDT is_VBZ discussed_VBN above_IN ,_, safety_NN is_VBZ also_RB important_JJ ._SENT The_DT problems_NNS associated_VBN with_IN corticosteroids_NNS occurred_VBN in_IN those_DT studies_NNS that_WDT used_VBD high_JJ doses_NNS (_( 1_CD --_: 2_CD g_NN methylprednisolone_NN )_) ._SENT When_WRB lower_JJR doses_NNS (_( 200_CD --_: 300_CD mg/day_NN of_IN hydrocortisone_NN )_) were_VBD used_VBN ,_, superinfection_NN and_CC other_JJ complications_NNS were_VBD not_RB observed_VBN ._SENT The_DT one_CD study_NN that_WDT did_VBD have_VB a_DT complication_NN was_VBD the_DT study_NN conducted_VBN by_IN Briegel_NP and_CC colleagues_NNS ._SENT Patients_NNS developed_VBD hyponatraemia_NN and_CC increased_VBN alanine_NN aminotransferase_NN levels_NNS at_IN day14_NN ._SENT The_DT hyponatraemia_NN was_VBD probably_RB related_VBN to_TO the_DT continuous_JJ infusion_NN ._SENT What_WP should_MD one_PP do_VB at_IN the_DT present_JJ time_NN ?_SENT For_IN routine_JJ use_NN of_IN low_JJ doses_NNS of_IN corticosteroids_NNS in_IN septic_JJ shock_NN ,_, there_EX are_VBP minimal_JJ or_CC no_DT risks_NNS ._SENT There_EX are_VBP data_NNS to_TO suggest_VB that_IN relative_JJ adrenal_JJ insufficiency_NN is_VBZ a_DT common_JJ problem_NN in_IN the_DT majority_NN of_IN patients_NNS with_IN septic_JJ shock_NN ._SENT Therefore_RB ,_, physicians_NNS can_MD reverse_VB shock_NN and_CC improve_VB survival_NN with_IN corticosteroids_NNS ,_, as_RB was_VBD shown_VBN in_IN the_DT prospective_JJ ,_, double-blind_JJ study_NN reported_VBN by_IN Annane_NP and_CC colleagues_NNS ._SENT One_PP should_MD be_VB aware_JJ that_IN ,_, in_IN the_DT study_NN by_IN Annane_NP and_CC colleagues_NNS ,_, patients_NNS were_VBD in_IN septic_JJ shock_NN with_IN systolic_JJ blood_NN pressure_NN below_IN 90_CD mmHg_NN for_IN more_JJR than_IN 1_CD hour_NN ._SENT This_DT is_VBZ not_RB the_DT usual_JJ patient_NN because_IN most_JJS respond_VB to_TO fluids_NNS and_CC vasopressors_NNS within_IN an_DT hour_NN ._SENT In_IN summary_NN ,_, in_IN the_DT typical_JJ septic_JJ shock_NN patient_NN ,_, based_VBN on_IN the_DT data_NNS we_PP already_RB have_VBP ,_, given_VBN the_DT frequency_NN of_IN relative_JJ adrenal_JJ insufficiency_NN in_IN this_DT population_NN and_CC the_DT lack_NN of_IN a_DT downside_NN to_TO the_DT use_NN of_IN lower_JJR doses_NNS of_IN corticosteroids_NNS ,_, the_DT routine_JJ use_NN of_IN corticosteroids_NNS is_VBZ probably_RB beneficial_JJ ._SENT If_IN physicians_NNS do_VBP not_RB want_VB to_TO use_VB them_PP early_JJ ,_, then_RB they_PP should_MD wait_VB a_DT few_JJ days_NNS so_RB as_RB not_RB to_TO worry_VB about_IN superinfection_NN ._SENT PST_NP received_VBD an_DT honorarium_NN from_IN the_DT International_NP Sepsis_NP Forum_NP for_IN helping_VBG to_TO write_VB this_DT commentary_NN ._SENT ACTH_NN =_SYM adrenocorticotrophic_JJ hormone_NN ._SENT 